Article Text

Download PDFPDF
P138 Time trends for incidence and survival of epithelial ovarian, fallopian tube, peritoneal and undesignated site cancer in sweden 1960–2014 – a population-based survey of cancer registry data
  1. P Leandersson1,
  2. T Högberg2,
  3. P Dickman3,
  4. S Malander4 and
  5. C Borgfeldt5
  1. 1Reproductive Medicine Centre, Skåne University Hospital, Lund University, Malmö
  2. 2Dept of Cancer Epidemiology, Skåne University Hospital, Lund University, Lund
  3. 3Dept of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm
  4. 4Dept of Oncology and Pathology, Skåne University Hospital
  5. 5Dept of Obstetrics and Gynecology, Skåne University Hospital, Lund University, Lund, Sweden

Abstract

Introduction/Background Analysis of survival trends in epithelial ovarian cancer with regard to age, tumour site and morphological subgroup in Sweden 1960 to 2014.

Methodology Nation-wide population-based study on data from the Swedish Cancer Registry. 46 350 women aged 18 or older with a diagnosis of epithelial ovarian, fallopian tube, peritoneal or undesignated site cancer 1960 to 2014 were included. Analyses of age-standardised incidence and relative survival (RS) were done and time trend graphs modelled according to age, tumour site and morphological subgroup.

Results Overall incidence of ovarian, tubal, peritoneal and undesignated site cancer declined since 1980. Median age at diagnosis increased. Serous cancer increased in incidence. RS at 1-, 2- and 5-years improved since 1960 although not for the youngest and the oldest patients. 10-year RS did not improve. Best RS was found for fallopian tube cancer and worst RS for undesignated site cancer. Among the histological subgroups endometrioid cancer had the best RS. RS improved most for endometrioid and mucinous cancer.

Conclusion Survival in epithelial ovarian, tubal, peritoneal and undesignated site cancer in Sweden has improved over the last six decades. Advances in epithelial ovarian cancer treatment have extended life for the first 5 years from diagnosis but not long-term survival.

Disclosure Nothing to disclose.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.